Skip to main content

Lifelong Management of Hypertension

  • Book
  • © 1983

Overview

Part of the book series: Developments in Cardiovascular Medicine (DICM, volume 26)

This is a preview of subscription content, log in via an institution to check access.

Access this book

eBook USD 16.99 USD 39.99
Discount applied Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book USD 16.99 USD 54.99
Discount applied Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

Table of contents (17 chapters)

  1. Introduction

  2. Epidemiology

  3. Pharmacology of antihypertensive agents

  4. How and whom to treat

  5. Prevention of hypertension and its complications

  6. Hypertension as a problem for society

Keywords

About this book

In the thirty years since the advent of efTective pharmacologic treatment for hypertension, the world ofthe hypertensive has been transformed beyond recog­ nition. The first change involved only malignant hypertensives with enough residual renal parenchyma to survive. Such a hypertensive could trade inevitable renal failure - unless an intracerebral bleed occurred first - for a rigid regimen which prevented his blood pressure from destroying him but which was asso­ ciated with nearly intolerable side effects. Over the next 20 years, increasing numbers of patients with hypertension of decreasing severity were treated with drugs that had fewer and fewer side effects. In 1970, with the medical world finally ready to accept the concept, the well-known Veterans Administration Study demonstrated that morbidity and mortality could be diminished in mode­ rately hypertensive patients by antihypertensive therapy that had minimal side effects. As a result there has been a major attempt to bring everyone with elevated blood pressure under lifelong pharmacologic control. It is difficult, however, to know what levels ofblood pressure deserve treatment; many who, when therapy first became available, would not have even been considered hypertensive are now candidates for treatment. The lower the pressure, the larger the potential population to be treated, but the smaller the individual risk and hence the smaller the possible benefit. The point where decades of diminished quaiity of life from treatment begins to outweigh a possible late-life complication is yet to be de­ termined.

Editors and Affiliations

  • U.S. Veterans Administration, USA

    H. Mitchell Perry

  • Hypertension Division Department of Medicine, Washington University School of Medicine, Saint Louis, USA

    H. Mitchell Perry

Bibliographic Information

  • Book Title: Lifelong Management of Hypertension

  • Editors: H. Mitchell Perry

  • Series Title: Developments in Cardiovascular Medicine

  • DOI: https://doi.org/10.1007/978-94-009-6732-8

  • Publisher: Springer Dordrecht

  • eBook Packages: Springer Book Archive

  • Copyright Information: Martinus Nijhoff Publishers, Boston 1983

  • Hardcover ISBN: 978-0-89838-582-3Due: 30 November 1983

  • Softcover ISBN: 978-94-009-6734-2Published: 11 November 2011

  • eBook ISBN: 978-94-009-6732-8Published: 06 December 2012

  • Series ISSN: 0166-9842

  • Edition Number: 1

  • Number of Pages: 268

  • Topics: Cardiology

Publish with us